ProShare Advisors’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $924K | Sell |
17,309
-2,420
| -12% | -$129K | ﹤0.01% | 850 |
|
|
2025
Q1 | $799K | Sell |
19,729
-2,669
| -12% | -$108K | ﹤0.01% | 880 |
|
|
2024
Q4 | $623K | Buy |
22,398
+5,477
| +32% | +$152K | ﹤0.01% | 1150 |
|
|
2024
Q3 | $485K | Buy |
16,921
+4,410
| +35% | +$127K | ﹤0.01% | 1153 |
|
|
2024
Q2 | $294K | Sell |
12,511
-2,490
| -17% | -$58.4K | ﹤0.01% | 1302 |
|
|
2024
Q1 | $379K | Buy |
15,001
+2,945
| +24% | +$74.4K | ﹤0.01% | 1266 |
|
|
2023
Q4 | $282K | Buy |
12,056
+1,753
| +17% | +$40.9K | ﹤0.01% | 1427 |
|
|
2023
Q3 | $521K | Buy |
10,303
+880
| +9% | +$44.5K | ﹤0.01% | 900 |
|
|
2023
Q2 | $440K | Buy |
9,423
+2,078
| +28% | +$97K | ﹤0.01% | 1026 |
|
|
2023
Q1 | $281K | Sell |
7,345
-1,008
| -12% | -$38.6K | ﹤0.01% | 1252 |
|
|
2022
Q4 | $458K | Buy |
8,353
+2,104
| +34% | +$115K | ﹤0.01% | 1004 |
|
|
2022
Q3 | $213K | Buy |
+6,249
| New | +$213K | ﹤0.01% | 1365 |
|
|
2022
Q1 | – | Sell |
-10,529
| Closed | -$223K | – | 2199 |
|
|
2021
Q4 | $223K | Sell |
10,529
-211
| -2% | -$4.47K | ﹤0.01% | 1962 |
|
|
2021
Q3 | $240K | Sell |
10,740
-2,189
| -17% | -$48.9K | ﹤0.01% | 1695 |
|
|
2021
Q2 | $321K | Buy |
12,929
+4,506
| +53% | +$112K | ﹤0.01% | 1853 |
|
|
2021
Q1 | $244K | Buy |
8,423
+63
| +0.8% | +$1.83K | ﹤0.01% | 1922 |
|
|
2020
Q4 | $216K | Buy |
8,360
+1,110
| +15% | +$28.7K | ﹤0.01% | 1808 |
|
|
2020
Q3 | $223K | Buy |
+7,250
| New | +$223K | ﹤0.01% | 1358 |
|